来源：徒步滚雪球 中波固收+，对于能容忍一定波动的同学来说，是非常适合配置的"压舱石"，等于是余额宝ProMAX。 去年12月，我更新了一次中波固收+文章，后来也在天天基金上尝试构建固收组合，计划把股赚的钱，往固收中转，也方便大家作业。 有朋友反馈这个好，感觉是值得坚持下去的事情。 上次更新到现在，已经有2个多月了，继续更新一波。 一、中波固收+的定义 根据权益仓位占比的不同，中波固收+产品权益仓位10%-20%，根据券商算法转债仓位按照40%折算权益仓位。 | 类型 | 权益仓位区间 | 主要产品类型 | 特征 | | --- | --- | --- | --- | | 低波 | ＞0％目＜10％ | 一级债基 | 以债券资产为主,权益占比较 低, 波动小、防御性强, 追求 | | | | | 稳健收益 | | 中波 | >10%且≤20% | 多数二级债基、 偏債混合基金 | 债券打底、权益适度增强,攻 守兼备,是市场上比较主流的 | | | | | 固收+类型 | | 高波 | >20% | 部分弹性较大的 偏债混合基金、 | 股票敞口较高,具备较强进攻 性与收益弹性,风险同步提升 | | | | 灵活 ...

Investment Rating - The industry rating is neutral, indicating that the overall return is expected to be between -5% and 5% relative to the CSI 300 index over the next six months [9]. Core Insights - AbbVie has submitted regulatory applications for its JAK inhibitor Rinvoq for the treatment of non-segmental vitiligo to both the FDA and EMA, based on positive results from the Phase 3 Viti-Up clinical study [5]. - The pharmaceutical sector showed a slight increase of +0.18% on February 5, 2025, outperforming the CSI 300 index by 0.78 percentage points, ranking 8th among 31 sub-industries [4]. - Among sub-industries, hospitals (+0.81%), offline pharmacies (+0.74%), and medical R&D outsourcing (+0.49%) performed well, while other bioproducts (-0.99%), vaccines (-0.44%), and pharmaceutical distribution (-0.25%) lagged behind [4]. Sub-industry Summary - Chemical pharmaceuticals: No rating [3] - Traditional Chinese medicine production: No rating [3] - Biopharmaceuticals II: Neutral [3] - Other pharmaceutical industries: Neutral [3]

Core Insights - The total value of the top 500 companies in China increased by 21 trillion yuan (38%), reaching 77 trillion yuan, with an average value growth of 41.5 billion yuan, now at 153 billion yuan [4][5] - The entry threshold for the list rose to 34 billion yuan, an increase of 7.5 billion yuan from the previous year, marking a historical high [4][5] - The technology sector continues to be a growth engine, with significant increases in the number and market value of companies in semiconductor, biomedicine, artificial intelligence, and new energy sectors [4][6] Industry Performance - The semiconductor sector has emerged as a leading industry, surpassing life sciences to become the second-largest sector in the list, with TSMC's value increasing by 3.5 trillion yuan, making it the highest-valued private enterprise in China [6][7][12] - New entrants in the semiconductor industry have become crucial for growth, with 95 new companies on the list, including two new semiconductor firms valued over 100 billion yuan [7][12] - The life sciences sector remains robust, with companies like BeiGene and Hansoh Pharmaceutical showing significant value increases, indicating steady growth despite being overtaken by semiconductors [7][12] Regional Highlights - Shanghai has 57 companies on the list, an increase of 7 from the previous year, making it the city with the fastest growth in the number of listed companies [14][15] - The city is a preferred research and development base, with 101 companies establishing their main R&D facilities there, highlighting its strategic importance in the tech sector [14][15] - Shanghai's companies are primarily concentrated in high-tech sectors such as semiconductors and life sciences, aligning with national trends towards innovation-driven industries [15][16] Emerging Trends - Nearly 40% of this year's listed companies were not on the list four years ago, indicating a dynamic shift in the corporate landscape [6][13] - The focus on hard technology is evident, with a significant number of new companies in AI computing, consumer electronics, and new energy sectors [6][10] - The integration of the Yangtze River Delta region has fostered a collaborative development environment, with 161 companies from this area making it to the list, accounting for 32% of the total [16]

Group 1 - Heng Rui Medicine's HRS-4642 injection has been included in the list of breakthrough therapeutic varieties, aimed at treating advanced or metastatic pancreatic cancer with KRAS G12D mutation in combination with gemcitabine and albumin-bound paclitaxel, with a total R&D investment of approximately 254 million yuan [1] - Fenglong Co. announced a significant stock price increase of 491.97% from December 25, 2025, to February 5, 2026, and may apply for a trading suspension if prices continue to rise abnormally [2] - Aier Eye Hospital clarified that the reported Xiangyang Hengtai Kang is not affiliated with the company, but is a joint venture established by Aier Medical Investment Group and other investors [3] Group 2 - XWANDA's subsidiary reached a settlement with Weir Electric, which is expected to impact the company's net profit attributable to shareholders by 500 million to 800 million yuan in 2025 [4] - Tianzhong Precision Machine received a lawsuit from eight creditors of its former subsidiary, involving a claim of 108 million yuan [5] - Dongtian Micro plans to invest 400 million yuan to establish a global R&D center and manufacturing headquarters in Dongguan, focusing on precision optical components for optical communication [6] Group 3 - Lvtong Technology's industrial fund plans to invest 10 million yuan in Shenghao Optoelectronics, which specializes in testing equipment for optical communication chips [7] - Tiansheng New Materials has been investigated by the China Securities Regulatory Commission for suspected violations of information disclosure laws [8] - Yahui Long has been placed under investigation by the CSRC for suspected information disclosure violations [9] Group 4 - Longyun Co. plans to acquire 58% of Yuheng Film Industry through a share issuance, with the target company's valuation estimated between 450 million and 530 million yuan [10] - Hu Silicon Industry announced that the National Integrated Circuit Industry Investment Fund plans to reduce its stake by up to 3% [11] - Perfect World reported that its actual controller has reduced his stake by 1.70% through various transactions [12] Group 5 - Sanfu Co. announced that its shareholder, Tangshan Yuanheng Technology Co., intends to reduce its stake by up to 3% [13] - Wanshan Expressway plans to invest 5.42 billion yuan in the expansion of the G30 Lianhuo Expressway in Anhui [14] - New Hope reported sales of 1.1218 million pigs in January, generating revenue of 1.628 billion yuan [15]

Company News - Beijing Capital International Airport Co., Ltd. (00694.HK) expects a net loss of approximately RMB 6.0 billion to RMB 7.6 billion in 2025, a year-on-year reduction of about 45.3% to 56.8%, benefiting from the recovery in aviation market demand and enhanced cost control [1] - Times Electric (03898.HK) anticipates total operating revenue of approximately RMB 28.761 billion in 2025, a year-on-year increase of 15.46%, with a net profit of about RMB 4.105 billion, up 10.88% year-on-year [1] - Hong Kong Tong Holdings (00032.HK) issued a profit warning, expecting a year-on-year increase in profit attributable to shareholders to approximately HKD 660 million for the fiscal year 2025 [1] - Datang Environment Industry Group (01272.HK) issued a profit warning, expecting pre-tax profit to rise to approximately RMB 700 million to RMB 710 million in 2025 [1] Power Generation - Datang New Energy (01798.HK) completed power generation of 3.272 million MWh in January, a year-on-year increase of 6.69% [2] - Longyuan Power (00916.HK) achieved power generation of 7.1627 million MWh in January, a year-on-year growth of 12.05%, with wind power generation increasing by 8.11% and solar power generation rising by 42.25% [2] - Jiangshan Holdings (00295.HK) reported total power generation of approximately 18.3 thousand MWh in January, a year-on-year decrease of 22.13% [4] Real Estate - Yuexiu Property (00123.HK) reported contract sales of approximately RMB 4.201 billion in January, a year-on-year decline of about 36.4% [2] - Poly Real Estate (01238.HK) recorded total contract sales of approximately RMB 470 million in January, a year-on-year decrease of 31.98% [2] - Greenland Hong Kong (00337.HK) reported contract sales of approximately RMB 508 million in January, a year-on-year increase of about 287.79% [3] Other Developments - CloudTop New Drug (01952) received approval for the new drug application of Vedolizumab for treating moderate to severe ulcerative colitis in adults in China [4] - Zhonghang Science and Technology (02357.HK) plans to invest RMB 58 million to acquire a 10% stake in Zhonghang Jierui [4] - Kelun-Biotech (06990.HK) received approval for the fourth indication of its core product TROP2ADC for treating 2L+ HR+/HER2- breast cancer [4] Financing and Buyback Activities - Kingsoft Corporation (03888.HK) repurchased approximately 1.1142 million shares for about HKD 29.9994 million, with repurchase prices ranging from HKD 26.8 to HKD 27 [7] - Geely Automobile (00175.HK) repurchased approximately 1.665 million shares for about HKD 27.1612 million, with repurchase prices between HKD 15.94 and HKD 16.44 [7] - October Rice Field (09676.HK) repurchased 780,000 shares for approximately HKD 7.3357 million, with repurchase prices between HKD 9.3 and HKD 9.46 [7] - China Galaxy (06881.HK) completed the issuance of corporate bonds totaling RMB 6 billion [7]

Core Viewpoint - CITIC Securities has issued a "buy" rating for Baile Tianheng, setting a target price of no more than 1322 yuan, predicting a net profit of -760 million yuan for 2025 [1] Group 1: Financial Performance - As of the report's release, Baile Tianheng's A-share price was 282.30 yuan per share, having increased over tenfold since its listing two years ago [1] - The predicted price implies a potential increase of over 468%, with a market capitalization exceeding 546 billion yuan if the target price is reached [1] - However, four days later, Baile Tianheng announced an earnings forecast indicating a net profit of approximately -1.1 billion yuan for 2025, a year-on-year decline of about 129.67%, significantly worse than CITIC Securities' forecast [3] - The expected revenue for 2025 is around 2.5 billion yuan, reflecting a year-on-year decrease of approximately 57.06% [3] - Historical performance shows Baile Tianheng's net profit fluctuating dramatically, with figures of -100 million yuan, -282 million yuan, -781 million yuan, and 3.708 billion yuan from 2021 to 2024 [5] Group 2: Research and Development - Baile Tianheng has increased its R&D investment to accelerate product pipeline development, which has led to a significant rise in R&D expenses [3] - The company has 17 innovative drugs in clinical trials, with 6 in global trials, and is conducting over 100 clinical trials worldwide [7] - The core product Iza-bren has received priority review status from the National Medical Products Administration (NMPA) for new indications, which is a key reason for CITIC Securities' positive outlook [4] Group 3: Strategic Partnerships - Baile Tianheng's collaboration with Bristol-Myers Squibb (BMS) on Iza-bren is progressing well, achieving a milestone in the global II/III phase key registration clinical trial, resulting in a milestone payment of 250 million USD [3] - The previous year, the company received an irrevocable and non-deductible upfront payment of 800 million USD from BMS, which contributed to higher income recognition in the prior period compared to the current period [3]

文章还表示，金元顺安医疗健康、同泰大健康主题、华泰柏瑞远见智选等，成立以来跌幅也都在50%以 上。 陈铭杰2016年6月加入金元顺安基金管理有限公司，历任专户投资部投资经理等。2023年10月27日起任基金 经理，管理经验尚不足3年。 张海东曾任中原农业保险股份有限公司资产管理部总经理、中国人民健康保险股份有限公司投资管理部处 长、渤海证券北京西外大街营业部担任交易部经理兼客服务部经理、大通证券北京营业部担任柜台主管、 分析师，2025年5月加入金元顺安基金管理有限公司，从2025年8月25日担任基金经理。 2025年4季度的前十大重仓股为三生国健、百利天恒、迪哲医药、百普赛斯（301080）、百济神州、艾力 斯、药明康德（603259）、恒瑞医药（600276）、迈威生物、博瑞医药。 中国经济网北京2月6日讯 2月4日，智通财经发布《2021年成立的基金还拿不回本？五成亏损 问题究竟出在 哪？》一文。文中称，2021年大量主动权益基金密集成立，时间一晃过去四年多，A股重新站在4000点上 方，但2021年那一批在牛市尾声发车的基金却并没有集体扬眉吐气。智通财经记者以2021年成立并仍存续 的667只主动权益 ...

Group 1 - The total value of the top 500 companies in China increased by 21 trillion yuan (38%), reaching 77 trillion yuan, with an average value growth of 41.5 billion yuan, now at 1.53 trillion yuan [1][2] - The entry threshold for the list rose to 34 billion yuan, an increase of 7.5 billion yuan from the previous year, marking a historical high [1][2] - The technology sector continues to be a growth engine, with significant increases in the number and market value of companies in semiconductor, biomedicine, artificial intelligence, and new energy sectors [1][2] Group 2 - Nearly 40% of this year's listed companies were not on the list four years ago, with new entrants primarily from consumer electronics, AI computing, and new energy sectors [2] - The semiconductor industry surpassed the life sciences sector to become the second-largest industry in the list, with TSMC leading the growth [3] - Notable semiconductor companies include TSMC, which saw a value increase of 3.5 trillion yuan, and Cambrian, which grew by 370 billion yuan [3] Group 3 - The new energy sector also performed well, with CATL's value increasing by 690 billion yuan, and other companies like Sungrow and EVE Energy showing significant growth [4] - The Shanghai region had 57 companies on the list, an increase of 7 from the previous year, making it the city with the fastest growth in the number of listed companies [10] - Shanghai is a key research and development hub, with 101 companies establishing their main R&D bases there, reflecting its strong innovation capabilities [10][11] Group 4 - The STAR Market (科创板) has a strong presence in the list, with 45 companies, showcasing the focus on hard technology sectors like semiconductors and biomedicine [6][7] - The semiconductor sector is particularly prominent among STAR Market companies, with many of the highest-valued startups in this field [8] - The overall trend indicates that STAR Market companies are in a high-growth phase, aligning with the broader trend of nearly 40% of this year's companies being new entrants [9]

Core Viewpoint - Heng Rui Medicine's HRS-4642 injection has been included in the list of breakthrough therapies by the National Medical Products Administration, indicating a significant advancement in the treatment of advanced or metastatic pancreatic cancer with KRAS G12D mutations [1] Group 1 - The HRS-4642 injection is used in combination with gemcitabine and albumin-bound paclitaxel for first-line treatment [1]

Group 1 - Core viewpoint: Heng Rui Medicine's HRS-4642 injection has been included in the list of breakthrough therapeutic drugs by the National Medical Products Administration [1] - Drug name: HRS-4642 injection, application number: CXHL2400083, classified as a Class 1 chemical drug [2] - Proposed indication: To be used in combination with gemcitabine and albumin-bound paclitaxel for first-line treatment of advanced or metastatic pancreatic cancer with KRAS G12D mutation [2] Group 2 - Application date for HRS-4642: December 24, 2025 [2] - The application meets the requirements of the Drug Registration Management Measures and the announcement regarding the breakthrough therapeutic drug review procedures [2]